Academic Journal
Q1Kidney International
About Kidney International
Kidney International is a scholarly journal published by Elsevier B.V.. SCImago 2025 places it in Q1 with an SJR of 5.559 and an H-index of 342.
Its listed coverage is 1972-2026 and its research categories include Nephrology (Q1). The 2025 dataset reports 381 documents and 9273 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Chronic Kidney Disease and Diabetes, Dialysis and Renal Disease Management, Renal Diseases and Glomerulopathies, Acute Kidney Injury Research, Parathyroid Disorders and Treatments, Ion Transport and Channel Regulation.
Recent Research Articles
Latest publications matched automatically by ISSN.
From dysphagia to kidney disease: Alport syndrome with leiomyomatosis
Idris Boudhabhay, Corinne Antignac, Sylvain Bodard, Brice Gayet et al.
2026-10 · DOI: 10.1016/j.kint.2026.04.034Kidney Disease: Improving Global Outcomes (KDIGO) life cycle of guideline development series: part 2: from initiation to publication: the KDIGO guideline development process
Amara Sarwal, Laia Oliveras, Benjamin Lazarus, Gihad Nesrallah et al.
2026-10 · DOI: 10.1016/j.kint.2026.04.030Heme-induced kallikrein-kinin system activation in hemolytic uremic syndrome
Alexandra Gerogianni, Niklas Friberg, Markus Wendler, Sára Kellnerová et al.
2026-10 · DOI: 10.1016/j.kint.2026.05.034Uremic toxins and parathyroid hormone have distinct effects on bone
Fellype Carvalho Barreto, Ziad A. Massy
2026-10 · DOI: 10.1016/j.kint.2026.05.030IL-33 as a component of neutrophil extracellular traps mediates contrast-induced acute kidney injury by promoting ferroptosis in tubular epithelial cells
Mengqing Ma, Hao Zhang, Weijuan Deng, Xia Du et al.
2026-10 · DOI: 10.1016/j.kint.2026.06.039A cluster randomized controlled trial (GOAL trial) evaluated a comprehensive geriatric assessment for frail older people with chronic kidney disease
Benignus Logan, Andrea K. Viecelli, David W. Johnson, Tracy Comans et al.
2026-10 · DOI: 10.1016/j.kint.2026.05.015Authors’ response to “Angiotensin receptor-neprilysin inhibitors for kidney protection in heart failure and chronic kidney disease: is there still a place?”
Carolyn S.P. Lam, Biykem Bozkurt, Sadiya S. Khan, Magdalena Madero et al.
2026-10 · DOI: 10.1016/j.kint.2026.06.008in this issue
2026-10 · DOI: 10.1016/j.kint.2026.07.013Kidney Disease: Improving Global Outcomes (KDIGO) life cycle of guideline development series: part 1: introduction to a new series
Reem A. Mustafa, Amy Earley, Laia Oliveras, Amara Sarwal et al.
2026-10 · DOI: 10.1016/j.kint.2026.02.044Autoimmunoglobulin-triggered extracellular vesicles as new players in membranous nephropathy: friends or foes?
Agnès Petit-Paitel, Franck Bihl, Gérard Lambeau
2026-10 · DOI: 10.1016/j.kint.2026.02.031COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody–positive immune-complex nephritis
Anindita Nandi, Jigna N. Bathia, Sanjukta Poddar, Ravali P. Goud et al.
2026-10 · DOI: 10.1016/j.kint.2026.06.014Authors’ response to “Uremic toxins and parathyroid hormone have distinct effects on bone”
Rosilene M. Elias, Carolina S. Wagner, Rosa M.A. Moysés
2026-10 · DOI: 10.1016/j.kint.2026.05.031Editorial Board
2026-10 · DOI: 10.1016/s0085-2538(26)00646-0A rationale for C5 inhibition in severe Shiga toxin–producing Escherichia coli–associated hemolytic uremic syndrome
Paula A. Coccia, Laura F. Alconcher
2026-10 · DOI: 10.1016/j.kint.2026.04.042Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy
Hilda E. Fernandez, Pietro Canetta, Andrew S. Bomback, Miroslav Sekulic et al.
2026-10 · DOI: 10.1016/j.kint.2026.06.013African-specific variants at the GATM locus and genetic bias in creatinine-based GFR estimation
Atlas Khan, Krzysztof Kiryluk
2026-10 · DOI: 10.1016/j.kint.2026.06.049Subscription Information
2026-10 · DOI: 10.1016/s0085-2538(26)00647-2A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease
Dominique Joly, Moreno Ursino, Frank Bienaimé, Khalil El Karoui et al.
2026-10 · DOI: 10.1016/j.kint.2026.05.018Secondary thrombotic microangiopathy in children—a central role for the glycocalyx
Alison Lap-tak Ma, Laura Alconcher, Paula Coccia, Jack Wing-tak Wong et al.
2026-10 · DOI: 10.1016/j.kint.2026.04.047Interferon signature in anti-neutrophil cytoplasmic antibody–negative patients
Hugo Ilciukas Miquel, David De Saint Gilles, Cedric Rafat
2026-10 · DOI: 10.1016/j.kint.2026.04.024Reviews
Community Reviews
Version History
September 8, 2026 at 12:05 am
September 8, 2026